What You Ought to Know
- The Deal: Hims & Hers Health, Inc. has entered right into a definitive settlement to acquire Eucalyptus , a world digital well being firm, in a transaction valued at as much as $1.15 billion.
- The Goal: Eucalyptus is a powerhouse within the Australian market and operates client manufacturers like Juniper and Pilot. The corporate has served over 775,000 clients and presently boasts an annual income run-rate (ARR) north of $450M.
- The Technique: The acquisition is an enormous geographic land seize. It instantly positions Hims & Hers to increase into Australia and Japan, whereas deepening its current footprint within the UK, Germany, and Canada.
Eucalyptus by the Numbers
Based in 2019, Eucalyptus operates a “home of manufacturers” mannequin—together with names like Juniper and Pilot—that carefully mirrors the aesthetic and consumer-first method of Hims & Hers.
However Eucalyptus is greater than only a model match; it’s a income engine.
- ARR: The corporate presently has an annual income run-rate north of $450 million.
- Development: It has delivered triple-digit year-over-year ARR progress in every quarter of 2025.
- Scale: It has served over 775,000 clients and facilitated practically two million consultations.
Moreover, Eucalyptus brings crucial native regulatory experience. It’s the first Australian telehealth enterprise to obtain accreditation from the Australian Council on Healthcare Requirements (ACHS), proving its scientific rigor in a extremely regulated market.
“Healthcare challenges are international, and so is the demand for easier, clear, and extra personalised healthcare,” mentioned Andrew Dudum, founder and CEO of Hims & Hers. “With Eucalyptus, we won’t solely enter new markets, we’ll increase our capacity to serve clients globally.”
Financing the $1.15 Billion Deal
Regardless of the billion-dollar price ticket, Hims & Hers has structured the transaction to guard its steadiness sheet. Upon closing (anticipated in mid-2026), Hims & Hers can pay roughly $240 million in money. The rest of the $1.15 billion valuation consists of assured deferred funds over the next 18 months, plus earnout funds tied to particular monetary targets via early 2029. Crucially, Hims & Hers retains the choice to settle nearly all of these deferred and earnout funds in both money or inventory, financing the preliminary outlay with current money readily available.
Management Modifications
As a part of the combination, Tim Doyle, present CEO and co-founder of Eucalyptus, will transition into the position of SVP of Worldwide at Hims & Hers, overseeing the mixed firm’s international enterprise operations.
“We’ve spent 7 years serving to clients world wide discover the care that matches them, and we consider at the moment’s information can be a part of accelerating the motion in the direction of inexpensive healthcare for everybody,” mentioned Doyle.
